Larsucosterol

Star0

DB18079InvestigationalSmall molecule

Larsucosterol: Overview.

Mechanism: Pharmacologically active on Oxysterols receptor LXR-beta and Oxysterols receptor LXR-alpha
Curator reviewed
Formula / weight: C₂₇H₄₆O₅S · 482.72 g/mol (avg)
Also known as: 25-hydroxycholest-5-en-3.beta.-yl hydrogen sulfate · 5-cholesten-3.beta.-25-diol-3-sulfate · 5-cholesten-3.beta., 25-diol 3-sulfate · Cholest-5-ene-3,25-diol, 3-(hydrogen sulfate), (3.beta.)-
Code names: 25HC3S · DUR-928 · DV-928

Resolves to

Compound

UNIIUGX2V7MGMZCAS884905-07-1ChEMBLCHEMBL4802158

Structure

InChIKeyPIUZYOCNZPYXOA-ZHHJOTBYSA-NSMILES[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OS(O)(=O)=O)[C@H](C)CCCC(C)(C)O

Targets

P55055NR1H2Q13133NR1H3

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Larsucosterol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account